专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

US20040253227A1 Perioperative multivitamin protein beverage and additive for use in preparing an individual for fast surgical recovery 审中-公开
标题翻译：围手术期多种维生素蛋白饮料和添加剂，用于制备个体用于快速手术恢复
公开(公告)号：US20040253227A1
公开(公告)日：2004-12-16
申请号：US10725610
申请日：2003-12-02
发明人： Kenneth A. Martin , Teresa Leigh Barr
IPC分类号： A61K038/46 , A61K035/80 , A61K047/00
CPC分类号： A23L33/155 , A23L5/00 , A23L7/00 , A23L21/00 , A23L29/30 , A23L33/10 , A23L33/105 , A23L33/125 , A23L33/15 , A23L33/28 , A23V2002/00 , A61K31/355 , A61K31/375 , A61K31/445 , A61K31/7008 , A61K31/737 , A61K36/48 , A61K36/68 , A61K36/87 , A61K36/899 , A61K2300/00 , A23V2250/708 , A23V2250/7046 , A23V2250/204 , A23V2250/21 , A23V2250/2124
摘要： The perioperative multivitamin protein additive for promoting an anabolic state in a person, is made of from about 250 mg to about 2500 mg a digestive enzyme, such as bromelain, pepsin, amylase, protease, lipase, cellulase, lactase, alpha-g, glucoamylase, invertase, malt diastase, pectinase, xylanase, bromelain, betain, and trypsin, or combinations thereof; from about 50 mg to about 2500 mg of an amino acid; from about 200 mg to about 2000 mg of a sea plant; from about 10 mg to about 8000 mg of a flavoring; from 100 mg to 2500 mg o Vitamin A, Vitamin B, Vitamin D, Vitamin E, Vitamin K and calcium, complexes thereof, and combinations thereof; and from about 1000 mg to about 9000 mg of a fiber. The perioperative multivitamin protein additive can be added to an ingestible liquid in order to form a perioperative multivitamin protein beverage.
摘要翻译：用于促进人体中合成代谢状态的围手术期多种维生素蛋白质添加剂由约250mg至约2500mg的消化酶，例如菠萝蛋白酶，胃蛋白酶，淀粉酶，蛋白酶，脂肪酶，纤维素酶，乳糖酶，α-g，葡糖淀粉酶，转化酶，麦芽淀粉酶，果胶酶，木聚糖酶，菠萝蛋白酶，甜菜碱和胰蛋白酶，或其组合; 约50mg至约2500mg氨基酸; 从约200mg到约2000mg的海洋植物; 约10mg至约8000mg调味剂; 从100mg至2500mg维生素A，维生素B，维生素D，维生素E，维生素K和钙，其复合物及其组合; 和约1000mg至约9000mg的纤维。围手术期多种维生素蛋白质添加剂可添加到可摄入液体中，以形成围手术期多种维生素蛋白饮料。

2. 发明申请

US20040253223A1 Treatment of aging disorders in humans 失效
标题翻译：治疗人类老龄化障碍
公开(公告)号：US20040253223A1
公开(公告)日：2004-12-16
申请号：US10858091
申请日：2004-06-01
发明人： Victorio C. Rodriguez
IPC分类号： A61K038/46
CPC分类号： A61K33/30 , A61K31/00 , A61K38/51 , Y10S514/878 , Y10S514/879 , Y10S514/903
摘要： A method for the treatment and prophylaxis of conditions of aging in humans, such conditions of aging associated with a decreased presence of one or more cell-specific carbonic anhydrase enzymes. Such conditions include chronic neurodegenerative conditions including dementia such as Alzheimer's disease. The method comprises administering to the patient a pharmaceutically effective, non-toxic amount of a compound that increases the presence of one or more cell-specific carbonic anhydrase enzymes whose levels are reduced in the patient. Such compound may be the cell-specific carbonic anhydrase enzyme, a compound that when absorbed by the body reacts or dissociates to form the cell-specific carbonic anhydrase enzyme, or a compound that promotes the natural generation of the cell-specific carbonic anhydrase enzyme within the body.
摘要翻译：用于治疗和预防人类衰老状况的方法，与一种或多种细胞特异性碳酸酐酶的存在减少相关的老化状况。这些病症包括慢性神经退行性疾病，包括痴呆症如阿尔茨海默病。该方法包括向患者施用药物有效的无毒量的化合物，其增加患者体内水平降低的一种或多种细胞特异性碳酸酐酶的存在。这种化合物可以是细胞特异性碳酸酐酶，当被身体吸收时反应或解离形成细胞特异性碳酸酐酶的化合物或促进天然产生细胞特异性碳酸酐酶的化合物身体。

3. 发明申请

US20040241155A1 Dilution resistant viscoelastic compositions 失效
标题翻译：耐稀释粘弹性组合物
公开(公告)号：US20040241155A1
公开(公告)日：2004-12-02
申请号：US10882923
申请日：2004-06-30
发明人： Mandar V. Shah
IPC分类号： A61F002/16 , A61K038/46 , C08L001/00 , C08K003/00 , C08J003/00
CPC分类号： A61L24/043 , A61F9/00736 , A61K9/0019 , A61K9/0048 , A61K9/0051 , A61K47/20 , A61K47/34 , A61K47/36 , A61K47/38 , A61L31/041 , A61L31/042 , A61L2430/16 , C08L5/08
摘要： A method of performing intra-articular therapy and a dilution resistant viscoelastic composition are disclosed. One embodiment of the dilution resistant composition comprises a hyaluronate-based viscoelastic agent and a low viscosity, polymer-containing solution. The hyaluronate-based viscoelastic can be an aqueous solution sodium hyaluronate having an average molecular weight greater than 750,000 Daltons and a concentration by weight between 0.5% and 3%. The polymer-containing solution can contain a polymer selected from the group consisting of chondroitin sulfate and hydroxypropylmethylcellulose. One embodiment can comprise a polymer-containing solution containing hydroxypropylmethylcellulose at a concentration by weight from about 0.05% to about 5.0% and chondroitin sulfate at a concentration by weight from about 0.1 to about 7%.
摘要翻译：公开了进行关节内治疗的方法和耐稀释的粘弹性组合物。抗稀释组合物的一个实施方案包括基于透明质酸盐的粘弹性剂和低粘度的含聚合物溶液。基于透明质酸盐的粘弹性体可以是平均分子量大于750,000道尔顿且浓度在0.5％至3％之间的透明质酸钠水溶液。含聚合物的溶液可以含有选自硫酸软骨素和羟丙基甲基纤维素的聚合物。一个实施方案可以包含含有浓度为约0.05％至约5.0％的羟丙基甲基纤维素和浓度为约0.1至约7％的硫酸软骨素的含聚合物溶液。

4. 发明申请

US20040223963A1 Method for treating ischemic stroke with melatonin 审中-公开
标题翻译：用褪黑激素治疗缺血性脑卒中的方法
公开(公告)号：US20040223963A1
公开(公告)日：2004-11-11
申请号：US10770371
申请日：2004-02-02
发明人： Raymond Cheung , Shiu-Fun Pang
IPC分类号： A61K038/46 , A61K031/405
CPC分类号： A61K31/405 , A61K31/4045 , A61K31/428 , A61K49/0004
摘要： The present invention is directed to a method of treating a sudden onset of at least one neurological deficit in a subject. The sudden onset of neurological symptoms is an indicator of a possible stroke, also termed a cerebrovascular accident. The method comprises administering an effective amount of melatonin to the subject immediately after the sudden onset of at least one neurological deficit, and preferably within three hours of the sudden onset of the at least one neurological deficit. Preferably, the effective amount of melatonin is at least about 200 mg and less than about 1000 mg, although for a small child or infant the effective amount of melatonin may be less than about 200 mg while for a large adult it may be more than about 1000 mg. It is expected that the effective amount of melatonin is no more than about 1500 mg in almost all cases.
摘要翻译：本发明涉及治疗受试者中至少一种神经功能缺损突然发作的方法。神经症状的突然发作是可能的中风的指标，也称为脑血管意外。该方法包括在突然发生至少一种神经缺陷之后，优选在突发性至少一种神经缺陷的三小时内，向受试者施用有效量的褪黑激素。优选地，褪黑激素的有效量为至少约200mg且小于约1000mg，尽管对于小孩或婴儿来说，有效量的褪黑激素可以小于约200mg，而对于大成人，其可以大于约 1000毫克。预计在几乎所有情况下，褪黑激素的有效量不超过约1500mg。

5. 发明申请

US20040219139A1 Diagnosis and treatment of ALK-7 related disorders 审中-公开
标题翻译：诊断和治疗ALK-7相关疾病
公开(公告)号：US20040219139A1
公开(公告)日：2004-11-04
申请号：US10849518
申请日：2004-05-20
申请人： SUGEN, INC.
发明人： Gregory D. Plowman , Douglas Clary
IPC分类号： A61K038/46 , C07H021/04 , C12N009/16
CPC分类号： C12N9/1205 , C07K14/705 , C07K2319/00 , C12N9/16
摘要： The present invention relates to ALK-7 polypeptides, nucleic acids encoding such polypeptides, cells, tissues and animals containing such nucleic acids, antibodies to such polypeptides, assays utilizing such polypeptides, and methods relating to all of the foregoing. Methods for treatment, diagnosis, and screening are provided for ALK-7 related diseases or conditions characterized by an abnormal interaction between an ALK-7 polypeptide and an ALK-7 binding partner.

6. 发明申请

US20040170618A1 Specifically targeted catalytic antagonists and uses thereof 审中-公开
标题翻译：特异性靶向催化拮抗剂及其用途
公开(公告)号：US20040170618A1
公开(公告)日：2004-09-02
申请号：US10791628
申请日：2004-03-01
发明人： Benjamin G. Davis , John Bryan Jones , Richard R. Bott , Karl John Sanford , David Aaron Estell
IPC分类号： A61K038/46 , C12N009/50
CPC分类号： B82Y5/00 , A61K47/51 , A61K47/665 , A61K47/6898
摘要： This invention provides chimeric molecules that are catalytic antagonists of a target molecule. The catalytic antagonists of this invention preferably comprise a targeting moiety attached to an enzyme that degrades the molecule specifically bound by the targeting moiety. The catalytic antagonists of this invention thus bind to a target recognized by the targeting moiety (e.g., a receptor) the enzyme component of the chimera then degrades all or part of the target. This typically results in a reduction or loss of activity of the target and release of the chimeric molecule. The chimeric molecule is then free to attack and degrade another target molecule.
摘要翻译：本发明提供作为靶分子的催化拮抗剂的嵌合分子。本发明的催化拮抗剂优选包含与降解由靶向部分特异性结合的分子的酶连接的靶向部分。因此，本发明的催化拮抗剂与靶向部分识别的靶（例如受体）结合，嵌合体的酶组分然后降解靶的全部或部分。这通常导致靶的活性降低或丧失，并释放嵌合分子。然后嵌合分子可以自由地攻击和降解另一个靶分子。

7. 发明申请

US20030165485A1 Functional role and potential therapeutic use of Reelin, Gas6 and Protein S in relation to adult neural stem or progenitor cells 审中-公开
标题翻译：与成体神经干细胞或祖细胞相关的Reelin，Gas6和蛋白S的功能作用和潜在的治疗用途
公开(公告)号：US20030165485A1
公开(公告)日：2003-09-04
申请号：US10291171
申请日：2002-11-08
发明人： Goran Bertilsson , Anna Falk , Jonas Frisen , Jessica Heidrich , Kristina Hellstrom , Jarkko Kortesmaa , Per Lindquist , Hanna Lundh , Jacqueline McGuire , Alex Mercer , Cesare Patrone , Harriet Ronnholm , Lilian Wikstrom , Olof Zachrisson
IPC分类号： A61K038/46 , A61K039/395
CPC分类号： C12N5/0623 , A61K35/30 , A61K38/1709 , A61K38/177 , A61K38/36 , A61K48/00
摘要： The invention relates generally to methods of influencing central nervous system cells to produce progeny useful in the treatment of CNS disorders. More specifically, the invention includes methods of exposing a patient suffering from such a disorder to a reagent that modulates the proliferation, migration, differentiation and survival of central nervous system cells via Reelin, Gas6 or Protein S signaling. These methods are useful for reducing at least one symptom of the disorder.
摘要翻译：本发明一般涉及影响中枢神经系统细胞以产生可用于治疗CNS病症的后代的方法。更具体地，本发明包括将患有这种病症的患者暴露于通过Reelin，Gas6或蛋白S信号调节中枢神经系统细胞的增殖，迁移，分化和存活的试剂的方法。这些方法可用于减少至少一种症状。

8. 发明申请

US20030153062A1 Butyrylcholinesterase variant polypeptides with increased catalytic efficiency and methods of use 审中-公开
标题翻译：丁酰胆碱酯酶多肽具有增加的催化效率和使用方法
公开(公告)号：US20030153062A1
公开(公告)日：2003-08-14
申请号：US10032233
申请日：2001-12-20
发明人： Jeffry D. Watkins , James D. Pancook
IPC分类号： C07H021/04 , A61K038/46 , C12N009/16
CPC分类号： C12N9/18 , A61K38/00
摘要： The invention provides twenty-one butyrylcholinesterase variants having increased cocaine hydrolysis activity as well as the corresponding encoding nucleic acids. The invention further provides methods of hydrolyzing a cocaine-based butyrylcholinesterase substrate as well as methods of treating a cocaine-induced condition.
摘要翻译：本发明提供具有增加的可卡因水解活性的二十一种丁酰胆碱酯酶变体以及相应的编码核酸。本发明还提供水解可卡因的丁酰胆碱酯酶底物的方法以及治疗可卡因诱导的病症的方法。

9. 发明申请

US20030152566A1 Soluble CD40L (CD154) as a prognostic marker of atherosclerotic diseases 失效
标题翻译：可溶性CD40L（CD154）作为动脉粥样硬化疾病的预后标志物
公开(公告)号：US20030152566A1
公开(公告)日：2003-08-14
申请号：US10288253
申请日：2002-11-05
申请人： The Brigham and Women's Hospital, Inc.
发明人： Uwe Schonbeck , Paul Ridker , Peter Libby
IPC分类号： G01N033/53 , G01N033/567 , A61K038/46 , A61K031/573 , A61K031/192
CPC分类号： A61K38/1709 , G01N33/6893 , G01N2800/32 , G01N2800/323 , G01N2800/324
摘要： This invention involves the new use of a diagnostic test to determine the risk of atherosclerotic diseases such as myocardial infarction and stroke, particularly among individuals with no signs or symptoms of current disease and among nonsmokers. Further, this invention involves the new use of a diagnostic test to assist physicians in determining which individuals at risk will preferentially benefit from certain treatments designed either to prevent first or recurrent myocardial infarctions and strokes, or to treat acute and chronic cardiovascular disorders. Methods for treatment also are described.
摘要翻译：本发明涉及诊断测试的新用途，以确定动脉粥样硬化疾病如心肌梗塞和中风的风险，特别是在目前疾病无症状或非吸烟者的个体中。此外，本发明涉及诊断测试的新用途，以帮助医生确定处于危险中的哪些个体将优先受益于旨在预防第一次或复发性心肌梗死和中风的某些治疗，或治疗急性和慢性心血管疾病。也描述了治疗方法。

10. 发明申请

US20030113312A1 Skin barrier function and cohesion through enhanced stratum corneum acidification 审中-公开
标题翻译：皮肤屏障功能和内聚力通过增强角质层酸化
公开(公告)号：US20030113312A1
公开(公告)日：2003-06-19
申请号：US10017038
申请日：2001-12-14
申请人： The Regents of the University of California
发明人： Peter M. Elias , Kenneth R. Feingold , Joachim W. Fluhr , Theodora M. Mauro , Martin J. Behne
IPC分类号： A61K038/46 , A61K031/685 , A61K031/66
CPC分类号： A61K31/685 , A61K31/00 , A61K38/465 , C12Y301/01004
摘要： The integrity, barrier function, cohesion and antimicrobial defense of the stratum corneum pH are improved by acidification, which is achieved by the application of low pH buffers, enzymes, phospholipids or salts with monovalent cations.
摘要翻译：通过酸化改善了角质层pH的完整性，屏障功能，内聚力和抗微生物防御性，其通过使用低pH缓冲液，酶，磷脂或与一价阳离子的盐来实现。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式